United States: These 28 Drugs Face Patent Expirations and Generic Entry From 2022 - 2023

Generic name: trabectedin
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: October 23, 2022
Generic Entry Controlled by: United States FDA Regulatory Exclusivity

YONDELIS is a drug marketed by Janssen Prods. There is one patent protecting this drug. One tentatively approved generic is ready to enter the market.

This drug has forty-four patent family members in thirty-six countries. There has been litigation on patents covering YONDELIS

See drug price trends for YONDELIS.

The generic ingredient in YONDELIS is trabectedin. There are four drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the trabectedin profile page.

Generic name: fluocinolone acetonide; hydroquinone; tretinoin
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: October 25, 2022
Generic Entry Controlled by: United States Patent Patent 8,653,053

TRI-LUMA is a drug marketed by Galderma Labs Lp. There are four patents protecting this drug.

This drug has twenty-nine patent family members in eighteen countries.

See drug price trends for TRI-LUMA.

The generic ingredient in TRI-LUMA is fluocinolone acetonide; hydroquinone; tretinoin. There are twelve drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the fluocinolone acetonide; hydroquinone; tretinoin profile page.

Generic name: sulfur hexafluoride lipid-type a microspheres
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: November 13, 2022
Generic Entry Controlled by: United States FDA Regulatory Exclusivity

LUMASON is a drug marketed by Bracco. There are two patents protecting this drug.

This drug has ten patent family members in nine countries.

See drug price trends for LUMASON.

The generic ingredient in LUMASON is sulfur hexafluoride lipid-type a microspheres. There are two drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the sulfur hexafluoride lipid-type a microspheres profile page.

Generic name: acyclovir; hydrocortisone
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: November 13, 2022
Generic Entry Controlled by: United States Patent Patent 7,223,387

XERESE is a drug marketed by Bausch. There is one patent protecting this drug.

This drug has twenty-five patent family members in twenty-one countries.

See drug price trends for XERESE.

The generic ingredient in XERESE is acyclovir; hydrocortisone. There are fifty-six drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the acyclovir; hydrocortisone profile page.

Generic name: radium ra-223 dichloride
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: November 17, 2022
Generic Entry Controlled by: United States Patent Patent 6,635,234

XOFIGO is a drug marketed by Bayer Hlthcare. There is one patent protecting this drug.

This drug has thirty-four patent family members in twenty-one countries.

See drug price trends for XOFIGO.

The generic ingredient in XOFIGO is radium ra-223 dichloride. One supplier is listed for this generic product. Additional details are available on the radium ra-223 dichloride profile page.

Generic name: cocaine hydrochloride
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: December 14, 2022
Generic Entry Controlled by: United States FDA Regulatory Exclusivity

GOPRELTO is a drug marketed by Genus Lifesciences. There are twelve patents protecting this drug. There has been litigation on patents covering GOPRELTO

The generic ingredient in GOPRELTO is cocaine hydrochloride. There are three drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the cocaine hydrochloride profile page.

Generic name: angiotensin ii acetate
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: December 21, 2022
Generic Entry Controlled by: United States FDA Regulatory Exclusivity

GIAPREZA is a drug marketed by La Jolla Pharma. There are ten patents protecting this drug.

This drug has thirty-nine patent family members in twenty-one countries.

See drug price trends for GIAPREZA.

The generic ingredient in GIAPREZA is angiotensin ii acetate. There are five drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the angiotensin ii acetate profile page.

Generic name: cocaine hydrochloride
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: January 10, 2023
Generic Entry Controlled by: United States FDA Regulatory Exclusivity

NUMBRINO is a drug marketed by Cody Labs Inc.

This drug has thirty-nine patent family members in twenty-one countries.

See drug price trends for NUMBRINO.

The generic ingredient in NUMBRINO is cocaine hydrochloride. There are three drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the cocaine hydrochloride profile page.

Generic name: acetaminophen; ibuprofen
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: February 28, 2023
Generic Entry Controlled by: United States FDA Regulatory Exclusivity

ADVIL DUAL ACTION WITH ACETAMINOPHEN is a drug marketed by Glaxosmithkline.

This drug has thirty-nine patent family members in twenty-one countries.

The generic ingredient in ADVIL DUAL ACTION WITH ACETAMINOPHEN is acetaminophen; ibuprofen. There are sixty-six drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the acetaminophen; ibuprofen profile page.

Generic name: magnesium chloride; sodium bicarbonate; sodium chloride
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: March 04, 2023
Generic Entry Controlled by: United States Patent Patent 7,300,674

NORMOCARB HF 25 is a drug marketed by Dialysis Sups. There is one patent protecting this drug.

This drug has four patent family members in four countries.

The generic ingredient in NORMOCARB HF 25 is magnesium chloride; sodium bicarbonate; sodium chloride. There are one hundred and forty-six drug master file entries for this API. Additional details are available on the magnesium chloride; sodium bicarbonate; sodium chloride profile page.

Generic name: chlorhexidine gluconate; isopropyl alcohol
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: March 14, 2023
Generic Entry Controlled by: United States Patent Patent 7,241,065

CHLORAPREP ONE-STEP is a drug marketed by Becton Dickinson Co. There are two patents protecting this drug.

This drug has twelve patent family members in eleven countries.

The generic ingredient in CHLORAPREP ONE-STEP is chlorhexidine gluconate; isopropyl alcohol. There are fifty-eight drug master file entries for this API. Three suppliers are listed for this generic product. Additional details are available on the chlorhexidine gluconate; isopropyl alcohol profile page.

Generic name: defibrotide sodium
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: March 30, 2023
Generic Entry Controlled by: United States FDA Regulatory Exclusivity

DEFITELIO is a drug marketed by Jazz Pharms Inc. There are two patents protecting this drug.

This drug has twenty-five patent family members in sixteen countries.

See drug price trends for DEFITELIO.

The generic ingredient in DEFITELIO is defibrotide sodium. One supplier is listed for this generic product. Additional details are available on the defibrotide sodium profile page.

Generic name: naloxone hydrochloride; oxycodone hydrochloride
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: April 04, 2023
Generic Entry Controlled by: United States Patent Patent 9,907,793

TARGINIQ is a drug marketed by Purdue Pharma Lp. There are fifteen patents protecting this drug.

This drug has three hundred and five patent family members in forty-four countries. There has been litigation on patents covering TARGINIQ

The generic ingredient in TARGINIQ is naloxone hydrochloride; oxycodone hydrochloride. There are twelve drug master file entries for this API. Additional details are available on the naloxone hydrochloride; oxycodone hydrochloride profile page.

Generic name: methylene blue
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: April 08, 2023
Generic Entry Controlled by: United States FDA Regulatory Exclusivity

PROVAYBLUE is a drug marketed by Provepharm Sas.

This drug has three hundred and five patent family members in forty-four countries.

See drug price trends for PROVAYBLUE.

The generic ingredient in PROVAYBLUE is methylene blue. There are twenty-five drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the methylene blue profile page.

Generic name: aliskiren hemifumarate; amlodipine besylate; hydrochlorothiazide
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: May 16, 2023
Generic Entry Controlled by: United States Patent Patent 8,183,295

AMTURNIDE is a drug marketed by Novartis. There is one patent protecting this drug.

This drug has thirty-two patent family members in twenty-four countries.

The generic ingredient in AMTURNIDE is aliskiren hemifumarate; amlodipine besylate; hydrochlorothiazide. There are four drug master file entries for this API. Additional details are available on the aliskiren hemifumarate; amlodipine besylate; hydrochlorothiazide profile page.

Generic name: lofexidine hydrochloride
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: May 16, 2023
Generic Entry Controlled by: United States FDA Regulatory Exclusivity

LUCEMYRA is a drug marketed by Uswm.

This drug has thirty-two patent family members in twenty-four countries.

See drug price trends for LUCEMYRA.

The generic ingredient in LUCEMYRA is lofexidine hydrochloride. Additional details are available on the lofexidine hydrochloride profile page.

Generic name: citric acid; lactic acid; potassium bitartrate
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: May 22, 2023
Generic Entry Controlled by: United States FDA Regulatory Exclusivity

PHEXXI is a drug marketed by Evofem Inc. There are two patents protecting this drug.

This drug has forty-three patent family members in twenty-two countries.

See drug price trends for PHEXXI.

The generic ingredient in PHEXXI is citric acid; lactic acid; potassium bitartrate. There are five drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the citric acid; lactic acid; potassium bitartrate profile page.

Generic name: uridine triacetate
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: July 10, 2023
Generic Entry Controlled by: United States Patent Patent 6,258,795

VISTOGARD is a drug marketed by Wellstat Therap. There are two patents protecting this drug.

This drug has one hundred and seventy-five patent family members in twenty-one countries.

The generic ingredient in VISTOGARD is uridine triacetate. There are thirty-six drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the uridine triacetate profile page.

Generic name: uridine triacetate
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: July 10, 2023
Generic Entry Controlled by: United States Patent Patent 6,258,795

XURIDEN is a drug marketed by Wellstat Therap. There is one patent protecting this drug.

This drug has one hundred and seventy-five patent family members in twenty-one countries.

The generic ingredient in XURIDEN is uridine triacetate. There are thirty-six drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the uridine triacetate profile page.

Generic name: riboflavin 5'-phosphate sodium
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: July 15, 2023
Generic Entry Controlled by: United States FDA Regulatory Exclusivity

PHOTREXA is a drug marketed by Glaukos.

This drug has one hundred and seventy-five patent family members in twenty-one countries.

The generic ingredient in PHOTREXA is riboflavin 5'-phosphate sodium. There are ten drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the riboflavin 5'-phosphate sodium profile page.

Generic name: plerixafor
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: July 22, 2023
Generic Entry Controlled by: United States Patent Patent 7,897,590

MOZOBIL is a drug marketed by Genzyme. There are two patents protecting this drug and one Paragraph IV challenge. Three tentatively approved generics are ready to enter the market.

This drug has fifty-two patent family members in twenty-seven countries. There has been litigation on patents covering MOZOBIL

See drug price trends for MOZOBIL.

The generic ingredient in MOZOBIL is plerixafor. There are seven drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the plerixafor profile page.

Generic name: budesonide; formoterol fumarate; glycopyrrolate
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: July 23, 2023
Generic Entry Controlled by: United States FDA Regulatory Exclusivity

BREZTRI AEROSPHERE is a drug marketed by Astrazeneca Ab. There are eight patents protecting this drug.

This drug has one hundred and ninety-two patent family members in thirty-three countries.

The generic ingredient in BREZTRI AEROSPHERE is budesonide; formoterol fumarate; glycopyrrolate. There are twenty-two drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the budesonide; formoterol fumarate; glycopyrrolate profile page.

Generic name: cysteamine hydrochloride
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: August 19, 2023
Generic Entry Controlled by: United States FDA Regulatory Exclusivity

CYSTADROPS is a drug marketed by Recordati Rare.

This drug has one hundred and ninety-two patent family members in thirty-three countries.

See drug price trends for CYSTADROPS.

The generic ingredient in CYSTADROPS is cysteamine hydrochloride. There are six drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the cysteamine hydrochloride profile page.

Generic name: lisdexamfetamine dimesylate
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: August 24, 2023
Generic Entry Controlled by: United States Patent Patent 7,655,630

VYVANSE is a drug marketed by Takeda Pharms Usa. There are eighteen patents protecting this drug and one Paragraph IV challenge. Six tentatively approved generics are ready to enter the market.

This drug has one hundred and forty-eight patent family members in twenty-seven countries. There has been litigation on patents covering VYVANSE

See drug price trends for VYVANSE.

The generic ingredient in VYVANSE is lisdexamfetamine dimesylate. One supplier is listed for this generic product. Additional details are available on the lisdexamfetamine dimesylate profile page.

Generic name: telbivudine
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: September 11, 2023
Generic Entry Controlled by: United States Patent Patent 6,569,837

TYZEKA is a drug marketed by Novartis. There are two patents protecting this drug.

This drug has eleven patent family members in seven countries.

The generic ingredient in TYZEKA is telbivudine. There are two drug master file entries for this API. Additional details are available on the telbivudine profile page.

Generic name: anidulafungin
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: September 22, 2023
Generic Entry Controlled by: United States FDA Regulatory Exclusivity

ERAXIS is a drug marketed by Vicuron Holdings.

This drug has eleven patent family members in seven countries.

See drug price trends for ERAXIS.

The generic ingredient in ERAXIS is anidulafungin. There are two drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the anidulafungin profile page.

Generic name: pazopanib hydrochloride
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: October 19, 2023
Generic Entry Controlled by: United States Patent Patent 7,105,530

VOTRIENT is a drug marketed by Novartis. There is one patent protecting this drug.

This drug has forty patent family members in twenty-five countries.

See drug price trends for VOTRIENT.

The generic ingredient in VOTRIENT is pazopanib hydrochloride. There are five drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the pazopanib hydrochloride profile page.

Generic name: magnesium sulfate; potassium chloride; sodium sulfate
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: November 10, 2023
Generic Entry Controlled by: United States FDA Regulatory Exclusivity

SUTAB (COPACKAGED) is a drug marketed by

This drug has forty patent family members in twenty-five countries.

The generic ingredient in SUTAB (COPACKAGED) is magnesium sulfate; potassium chloride; sodium sulfate. There are one hundred and forty-six drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the magnesium sulfate; potassium chloride; sodium sulfate profile page.